Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis
Roflumilast foam demonstrated statistically significant improvement on the trial’s primary and multiple secondary endpoints Once-daily roflumilast foam demonstrated a favorable...